Summary

A research team led by Dr. Sheng Nengyin of the Kunming Institute of Zoology (KIZ) of the Chinese Academy of Sciences has reframed ZC4H2-associated rare disorder (ZARD)—a disorder marked by intellectual disability, developmental delays, muscle weakness and other neurological or physical abnormalities—as a "disease spectrum" rather than a condition driven by a single mechanism. Previously, the team demonstrated that ZC4H2 acts as a postsynaptic regulator of excitatory synaptic activity and brain cognition by modulating the protein stability of AMPA receptor subunits GluA1 and GluA2.

AI summaries can be wrong sometimes—always verify important details using the source article.